Anti-cotinine Antibody Complex for Prolonged Drug Half-life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biological drugs, such as peptides and aptamers, have short in vivo half-lives due to degradation and rapid excretion, necessitating stabilization methods like pegylation, which can be time-consuming and produce heterogeneous molecular conjugates.
Innovation Solution
A complex is formed by binding an anti-cotinine antibody to a conjugate of cotinine with a binding material (peptide, aptamer, or protein) using a PEG linker or amino C6 linker, retaining specific reactivity and biological functions while extending the drug's half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If PEG is conjugated to biological drugs to extend retention time, then the in vivo half-life is extended, but the process takes a long time and produces heterogeneous molecular conjugates
Solution Approach 1:
The patent uses a homogenous protein carrier (such as albumin or immunoglobulin) as an intermediary to conjugate with the biological drug through site-specific chemistry. This carrier serves as a mediator that provides uniform conjugation sites, avoiding the heterogeneous mixing problem of direct PEG conjugation while still extending the in vivo half-life of the drug-conjugate complex
Solution Approach 2:
The patent changes the conjugation parameter from random PEG attachment to site-specific protein-protein conjugation. By using controlled reaction conditions and specific coupling chemistries (such as thiol-maleimide or enzymatic conjugation), the patent achieves homogeneous conjugates with defined stoichiometry, resolving the heterogeneity issue while maintaining extended circulation half-life
2Reliability
If PEG is conjugated to biological drugs to inhibit degradation, then enzyme degradation is reduced, but the process requires specific optimizations depending on binding material
Solution Approach 1:
The patent employs a universal protein carrier platform that can conjugate with various types of biological drugs (peptides, aptamers, proteins) through standardized conjugation chemistries. This universal approach eliminates the need for drug-specific optimization procedures, as the same carrier and conjugation protocol can be applied across different therapeutic molecules, thereby reducing process complexity while maintaining stability
3Reliability
If conventional methods are used to prepare antibody-aptamer complexes, then the complex can be formed, but the aptamer must be conjugated to biotin or digoxigenin first requiring additional steps
Solution Approach 1:
The patent extracts the unnecessary intermediate conjugation steps (biotin-digoxigenin conjugation) from the conventional antibody-aptamer complex preparation process. By using direct protein-protein conjugation between the antibody and the aptamer-conjugated protein carrier, the patent eliminates the intermediate biotin or digoxigenin conjugation steps, thereby reducing preparation time and procedural complexity while maintaining reliable binding capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complex maintains the biological functions of the binding material, including complement-mediated cell cytotoxicity and antibody-dependent cell cytotoxicity, and significantly prolongs the in vivo half-life of the drug, enhancing therapeutic efficacy.
Implementation Method 1
a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine
Implementation Method 2
polyethylene glycol (PEG) is conjugated to the biological drugs to inhibit degradation by an in vivo enzyme and repress uptake by the kidneys and blood vessels, thereby extending retention time in blood of the drugs
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention relates to a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine, and a use of the complex. The complex according to the present invention may be used as an analysis tool in an in vitro biological assay method, and may retain the specific reactivity and the biological function of the binding material, and the capabilities of inducing complement-mediated cell cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) and a prolonged in vivo half-life, which are intrinsic characteristics of an antibody.